Disclosures: Jane Giang: Nothing to Disclose, Sophia Hurr: Nothing to Disclose, Alfred Barritt IV: Merck (Any division): Advisor, Madrigal: Consultant, Life Edit: Consultant, Boehringer Ingelheim: Consultant, Target-RWE: Consultant 1673 ASSESSING TRANSITIONS OF CARE AMONGST INPATIENTS WITH CIRRHOSIS DISCHARGED FROM A DIVERSE, URBAN LIVER TRANSPLANT CENTER: THE IMPORTANCE OF HEPATOLOGY INVOLVEMENT AND DISCHARGE DESTINATION Max Schechter 1 Katherine Ni 2 Zoe Verzani 3 Kimberline Chew 2 Jang Hyun Kim 2 Lewis Paulino 2 Danielle Garfunkel 2 Lital Aliasi-Sinai 4 Daniel Alvarez 2 Adejoke Johnson 2 Soaptarshi Paul 2 Hamza Sadhra 2 Clara Tow 2 Don Rockey 2 , 1 Albert Einstein College of Medicine, 2 Montefiore Medical Center, 3 Weill Cornell Medicine, 4 American Medical Prgm Tel Aviv Universit Background: Hospitalized patients with cirrhosis are at risk of readmission due to the severity and complexity of their disease
Retatrutide Retatrutide is a peptide therapy designed to aid in weight loss and metabolic health by targeting three key hormone receptors: GLP-1 (glucagon-like peptide-1), GIP (glucose-dependent insulinotropic polypeptide), and glucagon receptors
10.23736/s0393-3660.19.04300-6 218 NelsonM
BPC-157 and TB-500: Why Recovery Is Half the Muscle Growth Equation The rate-limiting factor in muscle growth for most trained individuals is not the amount of GH or IGF-1 circulating at any given time
